Correspondence 0001493152-26-013347 from FibroBiologics, Inc. (FBLG)
FibroBiologics, Inc.
Date: March 27, 2026 · CIK: 0001958777 · Accession: 0001493152-26-013347
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-294713
Letter
FIBROBIOLOGICS, INC.
E. Medical Center Blvd.
Suite
Houston, Texas 77598
March 27, 2026
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
F Street, N.E.
Washington, D.C. 20549
RE: FibroBiologics, Inc. (the "Company")
Registration Statement on Form S-1
Filed March 27, 2026
File No. 333-294713
Ladies and Gentlemen:
Pursuant to Rule 461(a) under the Securities Act of 1933, as amended, the Company hereby respectfully requests that the effective date of the Company's Registration Statement on Form S-1 (File No. 333-294713) be accelerated by the Securities and Exchange Commission to 5:15 P.M. (Eastern Time) on March 31, 2026, or as soon as practicable thereafter, unless the Company notifies you otherwise prior to such time.
We request that we be notified of such effectiveness by a telephone call to Barrett S. DiPaolo of Sichenzia Ross Ference LLP at 646-810-2173, and that such effectiveness also be confirmed in writing.
Very truly yours,
FibroBiologics, Inc.
Show Raw Text
CORRESP 1 filename1.htm FIBROBIOLOGICS, INC. 455 E. Medical Center Blvd. Suite 300 Houston, Texas 77598 March 27, 2026 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 RE: FibroBiologics, Inc. (the "Company") Registration Statement on Form S-1 Filed March 27, 2026 File No. 333-294713 Ladies and Gentlemen: Pursuant to Rule 461(a) under the Securities Act of 1933, as amended, the Company hereby respectfully requests that the effective date of the Company's Registration Statement on Form S-1 (File No. 333-294713) be accelerated by the Securities and Exchange Commission to 5:15 P.M. (Eastern Time) on March 31, 2026, or as soon as practicable thereafter, unless the Company notifies you otherwise prior to such time. We request that we be notified of such effectiveness by a telephone call to Barrett S. DiPaolo of Sichenzia Ross Ference LLP at 646-810-2173, and that such effectiveness also be confirmed in writing. Very truly yours, FibroBiologics, Inc. By: /s/ Ruben A. Garcia Name: Ruben A. Garcia Title: General Counsel